Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Trial of Aspirin and Arginine Restriction in Colorectal Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-12-21
Last Posted Date
2023-07-07
Lead Sponsor
University of California, Irvine
Target Recruit Count
24
Registration Number
NCT00578721
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, Orange, California, United States

Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?

Not Applicable
Conditions
Interventions
First Posted Date
2007-12-21
Last Posted Date
2007-12-21
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
110
Registration Number
NCT00578760
Locations
🇨🇦

Princess Margaret Hospital, Toronto, Ontario, Canada

Effect of Apple Flavanols on Risk of Cardiovascular Disease

First Posted Date
2007-12-05
Last Posted Date
2013-03-06
Lead Sponsor
Quadram Institute Bioscience
Target Recruit Count
26
Registration Number
NCT00568152
Locations
🇬🇧

Institue of Food Research, Norwich, Norfolk, United Kingdom

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2007-11-30
Last Posted Date
2024-02-02
Lead Sponsor
National Cancer Centre, Singapore
Target Recruit Count
1587
Registration Number
NCT00565708
Locations
🇦🇺

Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia

🇦🇺

Chris O'Brien Lifehouse, Clinical Research Centre, Camperdown, New South Wales, Australia

🇦🇺

Coffs Harbour Health Campus North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia

and more 64 locations

Laboratory Aspirin Resistance in Diabetics and Non-Diabetics

Not Applicable
Completed
Conditions
First Posted Date
2007-11-26
Last Posted Date
2008-06-10
Lead Sponsor
University of Aarhus
Target Recruit Count
210
Registration Number
NCT00563875
Locations
🇩🇰

Department of Clinical Biochemistry, Centre for Haemophilia and Thrombosis, Aarhus University Hospital Skejby, Aarhus N, Denmark

Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers

First Posted Date
2007-10-24
Last Posted Date
2008-07-16
Lead Sponsor
Javelin Pharmaceuticals
Target Recruit Count
30
Registration Number
NCT00548678
Locations
🇺🇸

Comprehensive Phase One, Miramar, Florida, United States

Nephropathy In Type 2 Diabetes and Cardio-renal Events

First Posted Date
2007-09-27
Last Posted Date
2020-08-03
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
850
Registration Number
NCT00535925
Locations
🇮🇹

Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy

Aspirin in Patients With Myocardial Infarction and Thrombocytopenia

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2007-07-16
Last Posted Date
2012-08-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
5
Registration Number
NCT00501345
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

A Phase III Study of Apixaban in Patients With Atrial Fibrillation

First Posted Date
2007-07-04
Last Posted Date
2018-06-15
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
6421
Registration Number
NCT00496769
Locations
🇺🇸

Stamford Therapeutics Consortium, Stamford, Connecticut, United States

🇺🇸

Kaiser Permanente Medical Center, West Los Angeles, Los Angeles, California, United States

🇺🇸

Southwest Heart, Tucson, Arizona, United States

and more 65 locations
© Copyright 2024. All Rights Reserved by MedPath